Trading-Off Quality of Life and Survival Time – Feasibility of Web-Based Discrete Choice Experiments For QLU-C10D Utility Elicitation in Cancer Patients

Abstract Purpose This study aims to develop a web-based education program among cancer patients undergoing treatment of systemic chemotherapy and to evaluate the effect of the program on symptom control, quality of life, self-efficacy, and depression. Methods A web-based education program was prepared in line with patient needs, evidence-based guidelines, and expert opinions and tested with 10 cancer patients. A single-blind, randomised controlled study design was applied at a medical oncology unit of a university hospital. Pretests were applied to 60 cancer patients undergoing systemic chemotherapy, and the patients (intervention:30, control: 30) were randomized. The intervention group used the web-based education program for three months, and they were allowed to communicate with researchers 24/7 via the website. The effectiveness of the web-based education program at baseline and after 12 weeks was evaluated. The CONSORT 2010 guideline was performed. Results Expert opinions were found to be compatible with each other (Kendall's Wa = 0.233, p=0.008). The difference between symptom control (p=0.026) and quality of life (p=0.001) during the three-month follow-up of the groups were statistically significant, and there was no difference between the groups in terms of self-efficacy and depression levels (p˃0.05). Conclusion The web-based education program was found to be effective in remote symptom management and improving the quality of life of cancer patients. Trial registration www.clinicaltrials.gov , NCT05076916 (12 October 2021, retrospectively registered)

Download Full-text

PD29-07 PROGRESS, A WEB-BASED RESOURCE FOR PROSTATE CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS

The Journal of Urology ◽

10.1016/j.juro.2018.02.1382 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Michael Diefenbach ◽

Shawna Hudson ◽

Allison Marziliano ◽

Sara Fleszar ◽

Erin Tagai ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Cancer Patients ◽

Web Based

Download Full-text

Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate

European Journal of Cancer ◽

10.1016/s0959-8049(99)80703-5 ◽

1999 ◽

Vol 35 ◽

pp. S83 ◽

Cited By ~ 5

Author(s):

I.J. Diel ◽

M.R. Lichinitser ◽

J.J. Body ◽

K. Schlosser ◽

J. Moecks ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Survival Time ◽

Cancer Patients ◽

Bone Disease ◽

Bone Pain ◽

Metastatic Bone Disease ◽

Breast Cancer Patients

Download Full-text

Validation of a novel diabetic retinopathy utility index using discrete choice experiments

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2019-313899 ◽

2019 ◽

Vol 104 (2) ◽

pp. 188-193 ◽

Cited By ~ 1

Author(s):

Eva K Fenwick ◽

Nick Bansback ◽

Alfred Tau Liang Gan ◽

Julie Ratcliffe ◽

Leonie Burgess ◽

...

Keyword(s):

Quality Of Life ◽

Diabetic Retinopathy ◽

Discrete Choice ◽

Convergent Validity ◽

Severe Disease ◽

Well Being ◽

Vision Impairment ◽

Discrete Choice Experiments ◽

Utility Index

Background/aimsTo validate a preference-based Diabetic Retinopathy Utility Index (DRU-I) using discrete choice experiment (DCE) methods and assess disutilities associated with vision-threatening DR (VTDR: severe non-proliferative DR, proliferative DR and clinically significant macular oedema) and associated vision impairment.MethodsThe DRU-I comprises five quality-of-life dimensions, including Visual symptoms, Activity limitation/mobility, Lighting and glare, Socio-emotional well-being and Inconvenience, each rated as no, some, or a lot of difficulty. The DRU-I was developed using a DCE comprising six blocks of nine choice sets which, alongside the EuroQoL-5D (EQ-5D-3L) and Vision and Quality of Life (VisQoL) utility instruments, were interviewer-administered to participants. To ensure the DRU-I was sensitive to severe disease, we oversampled patients with VTDR. Data were analysed using conditional logit regression.ResultsOf the 220 participants (mean±SD age 60.1±11.3 years; 70.9% men), 57 (29.1%) and 139 (70.9%) had non-VTDR and VTDR, respectively, while 157 (71.4%), 20 (9.4%) and 37 (17.3%) had no, mild or moderate/severe vision impairment, respectively. Regression coefficients for all dimensions were ordered as expected, with worsening levels in each dimension being less preferred (theoretical validity). DRU-I utilities decreased as DR severity (non-VTDR=0.87; VTDR=0.80; p=0.021) and better eye vision impairment (none=0.84; mild=0.78; moderate/severe=0.72; p=0.012) increased. DRU-I utilities had low (r=0.39) and moderate (r=0.58) correlation with EQ-5D and VisQoL utilities, respectively (convergent validity).DiscussionThe DRU-I can estimate utilities associated with vision-threatening DR and associated vision impairment. It has the potential to assess the cost-effectiveness of DR interventions from a patient perspective and inform policies on resource allocation relating to DR.

Download Full-text